Literature DB >> 16425997

Immunoglobulin G avidity in differentiation between early and late antibody responses to West Nile virus.

Janet L Fox1, Stuart L Hazell, Leslie H Tobler, Michael P Busch.   

Abstract

In 1999 West Nile virus (WNV) surfaced in the United States in the city of New York and spread over successive summers to most of the continental United States, Canada, and Mexico. Because WNV immunoglobulin M (IgM) antibodies have been shown to persist for up to 1 year, residents in areas of endemicity can have persistent WNV IgM antibodies that are unrelated to a current illness with which they present. We present data on the use of IgG avidity testing for the resolution of conflicting data arising from the testing of serum or plasma for antibodies to WNV. Thirteen seroconversion panels, each consisting of a minimum of four samples, were used. All samples were tested for the presence of WNV IgM and IgG antibodies, and the avidity index for the WNV IgG-positive samples was calculated. Panels that exhibited a rise in the WNV IgM level followed by a sequential rise in the WNV IgG level were designated "primary." Panels that exhibited a marked rise in the WNV IgG level followed by a sequential weak WNV IgM response and that had serological evidence of a prior flavivirus infection were designated "secondary." All samples from the "primary" panels exhibited low avidity indices (less than 40%) for the first 20 to 30 days after the recovery of the index sample (the sample found to be virus positive). All of the "secondary" samples had elevated WNV IgG levels with avidity indices of > or =55%, regardless of the number of days since the recovery of the index sample. These data demonstrate that it is possible to differentiate between recent and past exposure to WNV or another flavivirus through the measurement of WNV IgG avidity indices.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16425997      PMCID: PMC1356611          DOI: 10.1128/CVI.13.1.33-36.2006

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  18 in total

1.  Validation of an in-house assay for cytomegalovirus immunoglobulin G (CMV IgG) avidity and relationship of avidity to CMV IgM levels.

Authors:  Harry E Prince; Amy L Leber
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

2.  A simple and cheaper in house varicella zoster virus antibody indirect ELISA.

Authors:  Erika Ono; Manuel Mindlin Lafer; Lily Yin Weckx; Celso Granato; Maria Isabel de Moraes-Pinto
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2004-07-20       Impact factor: 1.846

3.  Use of an immunoglobulin G avidity test to discriminate between primary and secondary dengue virus infections.

Authors:  Vanda Akico Ueda Fick de Souza; Silvana Fernandes; Evaldo Stanislau Araújo; Adriana Fumie Tateno; Olímpia M N P F Oliveira; Renato Reis Oliveira; Cláudio Sérgio Pannuti
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

4.  Detection of human parvovirus B19-specific IgM and IgG antibodies using a recombinant viral VP1 antigen expressed in insect cells and estimation of time of infection by testing for antibody avidity.

Authors:  J J Gray; B J Cohen; U Desselberger
Journal:  J Virol Methods       Date:  1993-09       Impact factor: 2.014

5.  Changes in antibody avidity after virus infections: detection by an immunosorbent assay in which a mild protein-denaturing agent is employed.

Authors:  S Inouye; A Hasegawa; S Matsuno; S Katow
Journal:  J Clin Microbiol       Date:  1984-09       Impact factor: 5.948

6.  Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence.

Authors:  Bharat S Parekh; M Susan Kennedy; Trudy Dobbs; Chou-Pong Pau; Robert Byers; Timothy Green; Dale J Hu; Suphak Vanichseni; Nancy L Young; Kachit Choopanya; Timothy D Mastro; J Steven McDougal
Journal:  AIDS Res Hum Retroviruses       Date:  2002-03-01       Impact factor: 2.205

7.  Persistence of West Nile Virus (WNV) IgM antibodies in cerebrospinal fluid from patients with CNS disease.

Authors:  Hema Kapoor; Kimberly Signs; Patricia Somsel; Frances P Downes; Patricia A Clark; Jeffrey P Massey
Journal:  J Clin Virol       Date:  2004-12       Impact factor: 3.168

8.  Reliability of immunoglobulin G antitoxoplasma avidity test and effects of treatment on avidity indexes of infants and pregnant women.

Authors:  Pierre Flori; Laetitia Tardy; Hugues Patural; Bahrie Bellete; Marie-Noëlle Varlet; Jamal Hafid; Hélène Raberin; Roger Tran Manh Sung
Journal:  Clin Diagn Lab Immunol       Date:  2004-07

9.  Immunoglobulin G antibody avidity assay for serodiagnosis of hepatitis C virus infection.

Authors:  Atsushi Kanno; Yukumasa Kazuyama
Journal:  J Med Virol       Date:  2002-10       Impact factor: 2.327

10.  Measurement of antibody avidity for hepatitis C virus distinguishes primary antibody responses from passively acquired antibody.

Authors:  K N Ward; W Dhaliwal; K L Ashworth; E J Clutterbuck; C G Teo
Journal:  J Med Virol       Date:  1994-08       Impact factor: 2.327

View more
  9 in total

1.  West nile virus.

Authors:  Georg Pauli; Ursula Bauerfeind; Johannes Blümel; Reinhard Burger; Christian Drosten; Albrecht Gröner; Lutz Gürtler; Margarethe Heiden; Martin Hildebrandt; Bernd Jansen; Thomas Montag-Lessing; Ruth Offergeld; Rainer Seitz; Uwe Schlenkrich; Volkmar Schottstedt; Johanna Strobel; Hannelore Willkommen
Journal:  Transfus Med Hemother       Date:  2013-07-04       Impact factor: 3.747

2.  Unusual patterns of IgG avidity in some young children following two doses of the adjuvanted pandemic H1N1 (2009) influenza virus vaccine.

Authors:  Karen K Yam; Jyotsana Gupta; Angela Brewer; David W Scheifele; Scott Halperin; Brian J Ward
Journal:  Clin Vaccine Immunol       Date:  2013-01-23

Review 3.  How to assess the binding strength of antibodies elicited by vaccination against HIV and other viruses.

Authors:  P J Klasse
Journal:  Expert Rev Vaccines       Date:  2016-01-06       Impact factor: 5.217

4.  High level antibody avidity is achieved in HIV-seropositive recipients of an inactivated split adjuvanted (AS03A) influenza vaccine.

Authors:  Karen K Yam; Erica Gipson; Marina Klein; Sharon Walmsley; David Haase; Scott Halperin; David Scheifele; Brian J Ward; Curtis Cooper
Journal:  J Clin Immunol       Date:  2014-05-14       Impact factor: 8.317

Review 5.  Diagnosis of west nile virus human infections: overview and proposal of diagnostic protocols considering the results of external quality assessment studies.

Authors:  Vittorio Sambri; Maria R Capobianchi; Francesca Cavrini; Rémi Charrel; Olivier Donoso-Mantke; Camille Escadafal; Leticia Franco; Paolo Gaibani; Ernest A Gould; Matthias Niedrig; Anna Papa; Anna Pierro; Giada Rossini; Andrea Sanchini; Antonio Tenorio; Stefania Varani; Ana Vázquez; Caterina Vocale; Herve Zeller
Journal:  Viruses       Date:  2013-09-25       Impact factor: 5.048

6.  The Application and Interpretation of IgG Avidity and IgA ELISA Tests to Characterize Zika Virus Infections.

Authors:  Fátima Amaro; María P Sánchez-Seco; Ana Vázquez; Maria J Alves; Líbia Zé-Zé; Maria T Luz; Teodora Minguito; Jesús De La Fuente; Fernando De Ory
Journal:  Viruses       Date:  2019-02-20       Impact factor: 5.048

7.  Chikungunya virus and West Nile virus infections imported into Belgium, 2007-2012.

Authors:  D VAN DEN Bossche; L Cnops; K Meersman; C Domingo; A VAN Gompel; M VAN Esbroeck
Journal:  Epidemiol Infect       Date:  2014-04-02       Impact factor: 4.434

Review 8.  The variability of the serological response to SARS-corona virus-2: Potential resolution of ambiguity through determination of avidity (functional affinity).

Authors:  Georg Bauer
Journal:  J Med Virol       Date:  2020-07-15       Impact factor: 20.693

9.  A fatal case report of antibody-dependent enhancement of dengue virus type 1 following remote Zika virus infection.

Authors:  Ashley N Bonheur; Sarah Thomas; Sara H Soshnick; Emily McGibbon; Alan P Dupuis; Rene Hull; Sally Slavinski; Paula E Del Rosso; Don Weiss; Danielle T Hunt; Megan E McCabe; Amy B Dean; Rebecca Folkerth; Anne M Laib; Susan J Wong
Journal:  BMC Infect Dis       Date:  2021-08-04       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.